1. Home
  2. VYGR vs KPTI Comparison

VYGR vs KPTI Comparison

Compare VYGR & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Voyager Therapeutics Inc.

VYGR

Voyager Therapeutics Inc.

HOLD

Current Price

$3.74

Market Cap

194.0M

Sector

Health Care

ML Signal

HOLD

Logo Karyopharm Therapeutics Inc.

KPTI

Karyopharm Therapeutics Inc.

HOLD

Current Price

$7.75

Market Cap

172.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VYGR
KPTI
Founded
2013
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
194.0M
172.6M
IPO Year
2015
2013

Fundamental Metrics

Financial Performance
Metric
VYGR
KPTI
Price
$3.74
$7.75
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
7
Target Price
$21.00
$17.50
AVG Volume (30 Days)
862.4K
603.7K
Earning Date
03-09-2026
02-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$10,135,000.00
$146,067,000.00
Revenue This Year
$54.19
N/A
Revenue Next Year
$20.22
$46.62
P/E Ratio
N/A
N/A
Revenue Growth
N/A
0.57
52 Week Low
$2.65
$3.51
52 Week High
$5.55
$10.99

Technical Indicators

Market Signals
Indicator
VYGR
KPTI
Relative Strength Index (RSI) 42.89 45.73
Support Level $3.36 $5.60
Resistance Level $3.74 $8.95
Average True Range (ATR) 0.32 0.73
MACD -0.06 -0.16
Stochastic Oscillator 4.87 30.11

Price Performance

Historical Comparison
VYGR
KPTI

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).

Share on Social Networks: